35 min ago
FDA Approves Gilead Sciences Drug for Three Cancers
The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer.
Trending on the Topix Network
5 hrs ago
Gilead Earnings Preview: Non-Sovaldi Sales Bogey May Be Unrealistic
Gilead Sciences, Inc. reports Q2 earnings tomorrow. Gilead is a biopharmaceutical company that develops and markets medicines for unmet needs.
Tue Jul 22, 2014
Doctors' Dilemma: Who Gets Costly Cure for Deadly Virus
Early this year, liver specialist Ken Flora and his colleagues sent letters to 1,300 patients announcing exciting news: powerful new drugs to cure the lethal hepatitis C virus were finally available.
Netflix falls on lower quarterly forecast
That's how much Netflix shares dropped on Tuesday after the streaming-video company forecast a profit of 89 cents a share, falling short of the $1.02 projected by analysts.
Mon Jul 21, 2014
Costly hepatitis C drugs could add $300 to every American's yearly premium, CVS says
Gilead Sciences' new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks.
Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?
Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed.
Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.
How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding?
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Fri Jul 18, 2014
Biotech Enters Reporting Season With Large Caps Central To Sector Performance
Biotech stock stocks enter their earnings season with investors increasingly interested in the long-term outlook for product pipelines, although large-cap growth stocks remain central to the sectors performance, an analyst said Friday.
NASH a Big Opportunity For Gilead Sciences, Inc.
After being a dominant player in the hepatitis C market with its drug Sovaldi, Gilead Sciences, Inc. is now eyeing to monetize from the next global epidemic, NASH, or nonalcoholic steatohepatitis.
Analyst Upgrades: Microsoft Corporation, Gilead Sciences, Inc., and Amgen, Inc.
Despite the blue chip's impressive year-to-date gain of 19%, most analysts remain on the fence when it comes to Microsoft Corporation.
Thu Jul 17, 2014
Could California spend $6.7 billion for hepatitis C drug?
This undated handout photo provided by Gilead Sciences shows the Hepatitis-C medication Sovaldi.
Most Active Options Update: Micron Technology, Inc.
The 20 stocks listed in the table below have attracted the highest total options volume during the past 10 trading days.
Wed Jul 16, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
InterGen Announces Agreement with IEnova to Close the Purchase of 50 Percent of the First Phase of the Energa Sierra Jurez Wind Project )--InterGen Announces Agreement with IEnova to Close the Purchase of 50 Percent of the First Phase of the Energia Sierra Juarez Wind Project )--Gilead Sciences, Inc. announced today that its second quarter 2014 ... (more)
Investor's Business Daily
Gilead Sciences to Release Second Quarter 2014 Financial Results on...
Gilead Sciences, Inc. announced today that its second quarter 2014 financial results will be released on Wednesday, July 23, at 4:05 p.m. Eastern Time.
That Model Genentech, Gilead Sciences, Inc., And Amgen Were Built On - Does It Work Anymore?
"The model is broken." I used to hear that chant from biotech VCs all the time, often accompanied by the thwack of self-flagellation.
Ranolazine Effectively Suppresses Atrial Fibrillation in the Setting...
From the Masonic Medical Research Laboratory, Utica, NY ; Department of Clinical and Biological Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY ; and Gilead Sciences, Foster City, CA .
Tue Jul 15, 2014
The Washington Post
J&J's Blockbuster Hepatitis C Sales Not Enough for Investors
While Johnson & Johnson's new hepatitis C pill Olysio has had blockbuster revenue in 2014, concerns the sales surge probably won't last drove down shares.
Mon Jul 14, 2014
Wyden battles drug maker over hep C drug price
Oregon U.S. Sen. Ron Wyden is one of many who want to know why the price of Sovaldi is so high.
Actavis plc (ACT), Gilead Sciences Inc. (GILD), Macquaire...
Bernard Selz 's Selz Capital recently disclosed at the SEC its long equity positions as of June 30 2014.